Rushton et al. reported strong FOLR1 positivity in 24.6% of low-grade serous ovarian cancers, especially in those lacking MAPK pathway mutations (BRAF, NRAS), suggesting a role for FRα-targeted therapies in molecularly stratified LGSOC subpopulations [25]. The gene discussed is FOLR1; the disease is ovarian serous adenocarcinoma.